SciSparc Corp (SPRC) - Koefisien utang jangka dawa marang modal

This price chart for SciSparc Ltd (SPRC) reflects the performance of a company developing mental health pharmaceuticals, where the separate_debt_long_eq metric stands at 0.00. The business faces clinical trial volatility and regulatory hurdles within the neurology sector. Meanwhile, management is implementing a rigorous scientific approach to CNS therapy, while a streamlined global raw material supplier network ensures the continuity of all production processes.

Investors view SciSparc Ltd (SPRC) as a promising asset within the specialized medicine sector. The 0.00 ratio measures the proportion of long-term liabilities within the equity structure, determining the financial stability and maturity of the business. The trajectory of long-term debt-to-equity reflects a balance between leveraged financing and autonomy. For SciSparc Ltd, this is critical when diversifying the development of drugs for dementia and Tourette syndrome. This security is classified as a high-risk biopharmaceutical asset.